Close Menu

NEW YORK (GenomeWeb) – German molecular diagnostics firm Curetis and BGI Group subsidiary MGI said today they plan to codevelop next-generation sequencing-based in vitro diagnostic assays for microbial infections.

The two firms have signed a broad memorandum of understanding to develop IVD assays targeting an array of pathogens and genetic and antibiotic resistance markers. The firms plan to combine Curetis' PCR platform, the Unyvero L4 Lysator, with MGI's SP100 Sample Preparation System and MGISeq NGS sequencers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.